Funding for this research was provided by:
National Heart, Lung, and Blood Institute (U10 HL074407, U10 HL074408, U10 HL074409, U10 HL074416, U10 HL074418, U10 HL074422, U10 HL074424, U10 HL074428, U10 HL074431, U10 HL074439, U10 HL074441)
Canadian Institutes of Health Research
Received: 2 June 2017
Accepted: 17 October 2017
First Online: 24 October 2017
Ethics approval and consent to participate
: Ethics approval was obtained at each study site in the original trials from which this secondary analysis was conducted. All participants provided informed consent.
: DDS has received advisory board honoraria, research funding and speaking fees from AstraZeneca, meeting honoraria and research funding from Boehringer Ingelheim, research funding from Merck Frosst, and advisory board honoraria from Novartis.DEN has received consulting fees from GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca.KEB, HV, JEC, and KMK declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.